Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest IMS Health Stories

2014-02-13 23:21:06

Healthcare Analytics Market research report covers the global market by type, application, delivery mode, component, end user, and geography. http://www.marketsandmarkets.com/Market-Reports/healthcare-data-analytics-market-905.html (PRWEB) February 13, 2014 The "Healthcare Analytics/Medical Analytics Market by Application (Clinical, Financial, & Operational), Type (Predictive, & Prescriptive), End-user (Payer, Provider, HIE, ACO), Delivery Mode (On-premise, Web, & Cloud)...

2014-01-23 16:24:38

PITTSBURGH, Jan. 23, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk's Prandin(®), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.(1) The company received final approval from the U.S. Food and Drug Administration (FDA) for its...

2014-01-09 23:24:22

The Diagnostics Marketing Association (DxMA) is pleased to announce the election of officers for 2014 and 2015. Indianapolis, IN (PRWEB) January 09, 2014 The Diagnostics Marketing Association (DxMA) is pleased to announce the election of officers for 2014 and 2015. Peggy Robinson will serve a two-year term as President, while Lawrence Worden will serve a two-year term as President-Elect. Additionally, Karen Alvarado will serve as Treasurer and Ned Gordon as Secretary. “I am sincerely...

2014-01-07 16:25:11

PITTSBURGH, Jan. 7, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release (ER) Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol® LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug...

2013-12-27 04:21:47

DUBLIN, December 27, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/ntfrwb/healthcare ) have announced the addition of the "Global Healthcare Analytics/Medical Analytics Market Report 2013-2017" [http://www.researchandmarkets.com/research/ntfrwb/healthcare ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Healthcare Analytics is the systematic use of data and related business insights...

2013-12-18 12:25:41

MUMBAI and BALTIMORE, December 18, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary Lupin Pharmaceuticals Inc. has launched its Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg / 300 mg in the US after the US District Court for the District of Delaware ruled that the Lupin's generic version of Trizivir(R) did not infringe on patents. Lupin had earlier received approval for the same. Lupin's...

2013-12-17 16:23:22

Agreement includes a no-later-than July 9, 2015 launch PITTSBURGH, Dec. 17, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. Bexarotene is the generic...

2013-12-13 12:23:33

DALLAS, December 13, 2013 /PRNewswire/ -- The "Healthcare Analytics/Medical Analytics Market by Application (Clinical, Financial, & Operational), Type (Predictive, & Prescriptive), End-user (Payer, Provider, HIE, ACO), Delivery Mode (On-premise, Web, & Cloud) - Trends & Global Forecasts to 2020", analyzes and studies the major market drivers, restraints, and opportunities in the U.S., Europe, Asia, and the Rest of the World. Browse 98 market data tables...

2013-12-05 08:29:16

PITTSBURGH, Dec. 5, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Cabergoline Tablets...

2013-12-02 16:23:28

John Daly, former Merck Executive, begins CTW consulting, offering expert frontline coaching, leadership development and pharmaceutical industry expertise to corporations such as IMS Health. NEW YORK, Dec. 2, 2013 /PRNewswire-iReach/ -- Former Merck executive, John Daly, recently founded CTW with two primary missions. (Photo: http://photos.prnewswire.com/prnh/20131202/MN25895) The first is to offer pharmaceutical industry consulting services to corporations such as IMS Health....